YahooAugust 30, 2026 at 10:00 PM NY4 days ago

Subsidised Access to Columvi® Now Available for Eligible Patients with Relapsed or Refractory DLBCL in Singapore

Columvi® (glofitamab) will be added to the Singapore Ministry of Health's (MOH) CDL and MAF List. Starting 1 September 2026, this milestone ensures that eligible Singaporeans and Permanent Residents will have subsidised access to the medication in public healthcare institutions.[1]

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — Yahoo

Read at Source

Companies in This Story

ROPRoper Technologies Inc406.96− 3.64%

Companies in This Story

Related Stories